Risk classification of clinically localized prostate cancer: Data from clinicopathological research for localized prostate cancer (CRPC)

Nishinihon Journal of Urology

Volumn 69, Issue 5, 2007, Pages 285-290

  Kuroiwa, Kentaro ^a   Goto, Ken ^a   Naito, Seiji ^a   Shiraishi, Taizo ^b   Kinukawa, Naoko ^c   Antoku, Yasuaki ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b MIE UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Prostate cancer; Prostatectomy; Risk classification

Indexed keywords

EID: 34250366211     PISSN: 00290726     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. D'Amico, A. V. et al.: Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95: 281-286, 2002.
2. Leibel, S. A. et al.: The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin. Oncol. 21: 580-597, 1994.
3. Pisansky, T. M. et al.: An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer 79: 2154-2161, 1997.
4. Roach, M. 3rd. et al.: Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int. J. Radiat. Oncol. Biol. Phys. 47: 617-627, 2000.
5. Shipley, W. U. et al.: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 281: 1598-1604, 1999.
6. Mitchell, J. A. et al.: Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J. Urol. 173: 1126-1131, 2005.
7. D'Amico, A. V.: Combined-modality staging for localized adenocarcinoma of the prostate. Oncology (Huntingt) 15: 1049-1075, 2001.
8. Partin, A. W. et al.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 277: 1445-1451, 1997.
9. Partin, A. W.: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58: 843-848, 2001.
10. Epstein, J. I. et al.: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 29: 1228-1242, 2005.
11. Albertsen, P. C. et al.: Prostate cancer and the Will Rogers phenomenon. J. Natl. Cancer Inst. 97: 1248-1253, 2005.
12. D'Amico, A. V. et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280: 969-974, 1998.
13. Oesterling, J. E. et al.: Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J. Urol. 138: 92-98, 1987.
14. Kattan, M. W. et al.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst. 90: 766-771, 1998.
15. Penson, D. F. et al.: How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J. Urol. 167: 1653-1658, 2002.
16. Graefen, M. et al.: Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients ? A validation study of the Partin tables. Eur. Urol. 43: 6-11, 2003.
17. Eskicorapci, S. Y. et al.: Validation of 2001 Partin tables in Turkey: a multicenter study. Eur. Urol. 47: 185-189, 2005.